J&J, Pharmacyclics’ Pill Keeps Leukemia at Bay in Study

Johnson & Johnson and Pharmacyclics Inc.’s experimental medicine ibrutinib helps keep a hard-to-treat form of the most common type of leukemia at bay for at least a year, U.S. researchers said.

To continue reading this article you must be a Bloomberg Professional Service Subscriber.